Qureshi W, Dar MA, Rather MY. New therapy for metabolic syndrome: Gut microbiome supplementation. World J Diabetes 2024; 15(9): 1833-1836 [PMID: 39280175 DOI: 10.4239/wjd.v15.i9.1833]
Corresponding Author of This Article
Waseem Qureshi, Doctor, FRCP, FRCPE, MBBS, MD, Chief Physician, Doctor, Professor, Superintendent, Hospital Administration, Government Medical College, University of Kashmir, Gole Market-10, Jammu and Kashmir, Srinagar 190010, India. qureshiwaseem786@gmail.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Sep 15, 2024; 15(9): 1833-1836 Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1833
New therapy for metabolic syndrome: Gut microbiome supplementation
Waseem Qureshi, Maqsood Ahmad Dar, Mohd Younis Rather
Waseem Qureshi, Hospital Administration, Government Medical College, University of Kashmir, Jammu and Kashmir, Srinagar 190010, India
Maqsood Ahmad Dar, Department of Medicine, Government Medical College, University of Kashmir, Jammu and Kashmir, Srinagar 190010, India
Mohd Younis Rather, Multidisciplinary Research Unit, Government Medical College, University of Kashmir, Jammu and Kashmir, Srinagar 190010, India
Author contributions: Qureshi W spearheaded the research and analysis, delving into the intricate relationship between metabolic syndrome and the gut microbiome, while also exploring emerging therapies; Dar MA and Rather MY provided invaluable insights from diverse perspectives, enriching the discourse with their expertise in biotechnology, microbiology, endocrinology, and therapeutic interventions. Together, our collaborative efforts synthesized complex scientific findings into a cohesive narrative, shedding light on the potential of gut microbiome supplementation as a novel therapeutic avenue for metabolic syndrome.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest related to the publication of this editorial. This includes any financial, personal, or professional relationships that could influence the content or interpretation of the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Noncommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Waseem Qureshi, Doctor, FRCP, FRCPE, MBBS, MD, Chief Physician, Doctor, Professor, Superintendent, Hospital Administration, Government Medical College, University of Kashmir, Gole Market-10, Jammu and Kashmir, Srinagar 190010, India. qureshiwaseem786@gmail.com
Received: March 14, 2024 Revised: May 21, 2024 Accepted: June 21, 2024 Published online: September 15, 2024 Processing time: 166 Days and 8 Hours
Abstract
The gut microbiota is important in the development and progression of metabolic illnesses such type 2 diabetes, cardiovascular disease (CVD), and obesity. This diverse community of microorganisms controls a variety of physiological functions, including metabolism, inflammation, and immune response. Understanding these interactions has resulted in novel therapeutic options, including microbiome supplementation. The gut microbiome is extremely susceptible to dietary changes, which can alter its makeup and function, influencing metabolite synthesis that affects host health. Certain metabolites, such as butyrate and propionate, have been proven to protect against metabolic illnesses, whereas trimethylamine has been linked to CVD. Prebiotics, probiotics, synbiotics, and postbiotics are being investigated by researchers as ways to change the gut microbiome and boost metabolic health. Despite advances in therapy and lifestyle adjustments, the prevalence of metabolic syndrome is increasing, emphasizing the need for new medicines.
Core Tip: The gut microbiota plays a crucial role in the onset and progression of metabolic conditions like type 2 diabetes, cardiovascular disease, and obesity. This diverse microbial community regulates various physiological functions, including metabolism, inflammation, and immune response. Understanding these interactions has led to innovative therapeutic approaches, such as microbiome supplementation. Dietary changes significantly impact the composition and function of the gut microbiome, influencing metabolite production that directly impacts host well-being. Certain metabolites like butyrate and propionate exhibit protective effects against metabolic disorders, while trimethylamine is associated with cardiovascular risk. Researchers explore prebiotics, probiotics, synbiotics, and postbiotics as potential avenues to modulate the gut microbiome and enhance metabolic health. Despite therapeutic advancements and lifestyle modifications, the prevalence of metabolic syndrome continues to rise, underscoring the urgent need for novel treatments.
